FDA Approves Breakthrough Glasses to Slow Nearsightedness in Children

Spread the Message

Read Time:4 Minute, 11 Second

December 2, 2025

WASHINGTON — In a significant milestone for pediatric eye care, the U.S. Food and Drug Administration (FDA) has granted market authorization for the first spectacle lenses designed to slow the progression of nearsightedness (myopia) in children. The approval, announced on September 25, 2025, offers a new, non-invasive treatment option for millions of families grappling with the rising rates of childhood vision issues.

The new lenses, marketed under the brand name Essilor Stellest, are authorized for children aged 6 to 12. Unlike standard glasses that merely correct blurry vision, these specialized lenses treat the underlying condition by slowing the abnormal elongation of the eye—a key factor in the progression of severe myopia.

The Silent Epidemic

Myopia is rapidly becoming a global health crisis. Characterized by the inability to see distant objects clearly, the condition has surged in prevalence, driven by genetic factors and lifestyle changes such as increased screen time and reduced outdoor activity.

“In the U.S., 30% to 40% of children will have myopia by the time they finish high school,” states Dr. Michael Repka, a professor and pediatric ophthalmologist at the Johns Hopkins School of Medicine.

For decades, the standard of care was reactive. “It was typically and simply: ‘Your child needs to wear glasses and they’ll live with it,'” Dr. Repka explains. “It will be lifelong and it will likely get worse over the next few years.”

This progression is not merely an inconvenience. High myopia significantly increases the risk of sight-threatening complications later in life, including cataracts, glaucoma, myopic maculopathy, and retinal detachment.

How the Technology Works

The newly approved Stellest lenses utilize a proprietary technology known as H.A.L.T. (Highly Aspherical Lenslet Target). To the naked eye, they look like regular glasses, but they contain a hidden power:

Correction Zone: The lens provides clear vision through a standard single-vision zone.
Treatment Zone: This area consists of 11 concentric rings of 1,021 tiny, invisible “lenslets” (raised dots).

These lenslets create a volume of signal light in front of the retina—a mechanism called “myopic defocus.” This signal acts as a brake, telling the eye to stop growing too long, effectively slowing the myopia progression.

Clinical Findings: A 71% Reduction

The FDA’s authorization was based on compelling clinical data reviewed through its De Novo pathway for novel medical devices. Key findings from the company’s two-year clinical trial included:

Slowed Progression: Children wearing the lenses 12 hours a day experienced an average 71% reduction in myopia progression compared to those wearing standard single-vision lenses.
Reduced Eye Growth: The lenses slowed the elongation of the eyeball (axial length) by approximately 53%.

“Now we have a way to slow that down and maybe we can prevent kids from having that really elongated eye that puts them at risk for blindness,” says Dr. Rupa Wong, a pediatric ophthalmologist based in Honolulu.

A New Alternative to Contact Lenses

Prior to this approval, the only FDA-authorized device for slowing myopia progression in children was MiSight, a daily disposable contact lens approved in 2019. While effective, contact lenses can be a hurdle for younger children or hesitant parents.

The introduction of a spectacle lens option fills a critical gap. Experts note that many parents prefer glasses for children as young as six due to ease of use and safety. The Stellest lenses are non-invasive and showed no serious adverse events in clinical trials, though some children reported minor visual disturbances such as halos, which typically resolved as they adapted to the lenses.

Cost and Availability

The suggested retail price for the lenses is approximately $450. While this is higher than standard lenses, many major U.S. vision insurance providers are expected to cover the product given its classification as a therapeutic device rather than just vision correction.

The lenses are rolling out to eye care practices across the U.S. immediately. Ophthalmologists advise that the best candidates are children with early-onset myopia or those with a strong family history of the condition.

Implications for Public Health

With the World Health Organization predicting that half the global population will be myopic by 2050, interventions that can alter the disease’s trajectory are vital. By managing myopia early, these devices may reduce the burden of severe eye disease in the coming decades.

While the current approval relies partly on data from studies conducted in Asia, further research is underway in the United States, supported by the National Institutes of Health (NIH), to confirm these results across diverse populations.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.